Michele Nichelatti

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Enrica Morra

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Roberto Cairoli

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Elide A. Pastorello

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Silvio Veronese

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Alessandra Tedeschi

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Andrea Sartore‐Bianchi

University of Milan

Salvatore Siena

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Francesca Ricci

Humanitas University

Aurelio Limido

ASST Fatebenefratelli Sacco

Umberto Maggiore

University of Parma

Cooperative Institutions

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

287

Istituti di Ricovero e Cura a Carattere Scientifico

239

Ospedale Maggiore

200

University of Milan

162

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

154

University of Turin

University of Pavia

University of Milano-Bicocca

Sapienza University of Rome

University of Bologna

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer

PLoS ONE (2009)

Andrea Sartore‐Bianchi Federica Di Nicolantonio Michele Nichelatti Francesca Molinari Sara De Dosso

Background KRAS mutations occur in 35–45% of metastatic colorectal cancers (mCRC) and preclude responsiveness to EGFR-targeted therapy with cetuximab or panitumumab. However, less than 20% patients displaying wild-type KRAS tumors achieve objective response. Alterations in other effectors downstream of the EGFR, such as BRAF, and deregulation of the PIK3CA/PTEN pathway have independently been found to give rise to resistance. We present a comprehensive analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression in mCRC patients treated with cetuximab or panitumumab, with the aim of clarifying the relative contribution of these molecular alterations to resistance. Methodology/Principal Findings We retrospectively analyzed objective tumor response, progression-free (PFS) and overall survival (OS) together with the mutational status of KRAS, BRAF, PIK3CA and expression of PTEN in 132 tumors from cetuximab or panitumumab treated mCRC patients. Among the 106 non-responsive patients, 74 (70%) had tumors with at least one molecular alteration in the four markers. The probability of response was 51% (22/43) among patients with no alterations, 4% (2/47) among patients with 1 alteration, and 0% (0/24) for patients with ≥2 alterations (p<0.0001). Accordingly, PFS and OS were increasingly worse for patients with tumors harboring none, 1, or ≥2 molecular alteration(s) (p<0.001). Conclusions/Significance When expression of PTEN and mutations of KRAS, BRAF and PIK3CA are concomitantly ascertained, up to 70% of mCRC patients unlikely to respond to anti-EGFR therapies can be identified. We propose to define as 'quadruple negative', the CRCs lacking alterations in KRAS, BRAF, PTEN and PIK3CA. Comprehensive molecular dissection of the EGFR signaling pathways should be considered to select mCRC patients for cetuximab- or panitumumab-based therapies.

Panitumumab

10.1371/journal.pone.0007287

Cite

Citations (261)

Life-Threatening Cerebral Hematoma Owing to Aneurysm Rupture

World Neurosurgery (2015)

Giuseppe Talamonti Michele Nichelatti Aysam Adnan Al Mashni Giuseppe D’Aliberti

Clipping (morphology)

Anterior cerebral artery

Concomitant

10.1016/j.wneu.2015.08.082

Cite

Citations (7)

Hypersensitivity to Tomato (Lycopersicon esculentum) in Peach-Allergic Patients: rPrup 3 and rPrup 1 Are Predictive of Symptom Severity.

PubMed (2015)

Ambra Mascheri Laura Farioli Valerio Pravettoni Marta Piantanida Chrysi Stafylaraki

Background: The role of allergens in the severity of tomato allergy symptoms has not yet been studied.To evaluate the relationship between severe allergic reactions to peach and tomato and between tomato allergy symptoms and the pattern of IgE positivity for rPru p 1, rPru p 3, rPru p 4, rBetv 1, rBetv 2, rBetv4, rPhl p 1, and rPhl p 12 in order to identify the role of recombinant allergens in the severity of reactions to tomato.We studied peach-allergic patients with clinical reactions to tomato by performing an open food challenge, skin prick test, and determination of serum specific IgE to tomato and to recombinant peach, birch, and grass allergens. Statistical analysis was carried out to evaluate the relationship between the severity of tomato symptoms and IgE positivity to the different allergens and to peach-induced symptoms.We found a significant association between severe reactions to tomato and severe reactions to peach (P = .01 7) and levels of IgE to rPru p3 (P = .029) and between mild tomato allergy symptoms and levels of IgE to rPru p1 (P = .047), anti-rBetv 1 (P = .0414), anti-rBetv 2 (P = .0457), and Phleum pratense (P = .0022).We observed a significant relationship between peach and symptoms of tomato allergy. IgE positivity for rPru p3 seems to be a surrogate biochemical marker for severe tomato allergy, whereas the presence of anti-rPru p 1 IgE may be an indicator of mild tomato allergy.

Lycopersicon

Oral allergy syndrome

Phleum

Source

Cite

Citations (21)

Verifying Hellström-Lindberg score as predictive tool for response to erythropoietin therapy according to the “International Working Group” criteria, in anemic patients affected by myelodysplastic syndrome: a monocentric experience

International Journal of Hematology (2013)

Alfredo Molteni Marta Riva Rosa Greco Michele Nichelatti Emanuele Ravano

Hematology

10.1007/s12185-013-1305-0

Cite

Citations (3)

Prospective monocentric study of non-tunnelled central venous catheter-related complications in hematological patients

Leukemia & lymphoma/Leukemia and lymphoma (2008)

Anna Maria Nosari Guido Nador Andrea De Gasperi G Ortisi Alberto Volonterio

Indwelling central venous catheters (CVCs) are used in the management of hematologic patients. However, insertion and maintenance of CVCs are susceptible to complications. Study design and methods data concerning 388 consecutive catheterisations, performed in oncohematologic patients between April 2003 and December 2004, were prospectively collected. At insertion thrombocytopenia was present in 109 cases (28.1%) and neutropenia in 67 (17.3%). Hemorrhage after CVC insertion occurred in five thrombocytopenic patients (1.3%). The median duration of catheterisation was 18.8 days (range 1-89), longer in the 7-French CVCs utilised in leukemic patients (24.3 days) and shorter in 12-French CVCs (11 days), used for PBSC harvesting. Deep venous thrombosis was diagnosed in 13 cases (3.3%). Ninety-two catheterisations (12.6/1000 days-catheter) were complicated by infections: 19 local infections (4.8%) and 73 (18.8%) bacteraemias of which 45 (11.6%) were catheter-related, mainly due to Gram positive germs (32/45, 71.1%). The frequency of catheter-related bacteraemia was 7.2 events/1000 days-catheter. Thirteen CVCs were removed due to thrombosis, 15 due to infections, 20 due to malfunction, the remaining 333 at patients discharge. At univariate analysis high-dose chemotherapy (p = 0.013), 7-Fr lumen (p = 0.023), acute myeloid leukemia (AML) (p = 0.001), duration of neutropenia >10 days and length of catheterisation were significantly correlated to infection. Multivariate analysis confirmed the duration of catheterisation, AML and high-dose chemotherapy as risk factors. Even though hematological in-patients are at increased risk for bleeding and infections, non-tunnelled CVCs offer a safe venous access also in patients affected by severe thrombocytopenia and prolonged neutropenia.

Univariate analysis

Central venous catheter

10.1080/10428190802409930

Cite

Citations (9)

On some Derivatives of Vector-Matrix Products Useful for Statistics

Current Trends on Biostatistics and Biometrics (2018)

Michele Nichelatti

Epilepsy is a chronic disorder of the brain that affects people of all ages. Approximately 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally. People with epilepsy respond to treatment approximately 70% of the time. About three fourths of people with epilepsy living in lowand middle- income countries do not get the treatment they need.

10.32474/ctbb.2018.01.000110

Cite

Citations (2)

Down-regulation of MicroRNAs 222/221 in Acute Myelogenous Leukemia with Deranged Core-Binding Factor Subunits

Neoplasia (2010)

Matteo Brioschi John A. Fischer Roberto Cairoli Stefano Rossetti Laura Anna Pezzetti

Core-binding factor leukemia (CBFL) is a subgroup of acutemyeloid leukemia (AML) characterized by genetic mutations involving the subunits of the core-binding factor (CBF). The leukemogenesis model for CBFL posits that one, or more, gene mutations inducing increased cell proliferation and/or inhibition of apoptosis cooperate with CBF mutations for leukemia development. One of the most commonmutations associated with CBF mutations involves the KIT receptor. A high expression of KIT is a hallmark of a high proportion of CBFL. Previous studies indicate that microRNA (MIR) 222/221 targets the 3′ untranslated region of the KIT messenger RNA and our observation that AML1 can bind the MIR-222/221 promoter, we hypothesized that MIR-222/221 represents the link between CBF and KIT. Here, we show that MIR-222/221 expression is upregulated after myeloid differentiation of normal bone marrow AC133+ stem progenitor cells. CBFL blasts with either t(8;21) or inv(16) CBF rearrangements with high expression levels of KIT (CD117) display a significantly lower level of MIR-222/221 expression than non-CBFL blasts. Consistently, we found that the t(8;21) AML1-MTG8 fusion protein binds the MIR-222/221 promoter and induces transcriptional repression of a MIR-222/221-LUC reporter. Because of the highly conserved sequence homology, we demonstrated concomitant MIR-222/221 down-regulation and KIT up-regulation in the 32D/WT1 mouse cell model carrying the AML1-MTG16 fusion protein. This study provides the first hint that CBFL-associated fusion proteins may lead to up-regulation of the KIT receptor by down-regulating MIR-222/221, thus explaining the concomitant occurrence of CBF genetic rearrangements and overexpression of wild type or mutant KIT in AML.

Core binding factor

10.1593/neo.10482

Cite

Citations (37)

4.4 ARSD Is a New Biomarker Associated with IgVH, ZAP-70, and Disease Progression in CLL

Clinical Lymphoma Myeloma & Leukemia (2011)

Alessandra Trojani Barbara Di Camillo Alessandra Tedeschi Milena Lodola Simona Montesano

Clinical Significance

10.1016/j.clml.2011.09.124

Cite

Citations (0)

Is Ashwell-Morell Receptor Mediated Hepatic Clearance of Platelet Clinically Relevant in Immune Thrombocytopenia (ITP)? a Retrospective Analysis of Platelet Kinetic Studies and Autoantibody Type Data